Simulations Plus, Inc.

NASDAQ:SLP

Medical - Healthcare Information Services

Healthcare
$18.50 +0.11%

+$0.02 today

Market cap
$374.16M
Beta
1.32
P/E (TTM)
-5.9
EPS (TTM)
-$3.12
52W Low $11.09High $21.01

Volume 0.00M

Average 0.35M

SLP EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Simulations Plus, Inc.NASDAQ: SLP

EBITDA · Q2 FY2026 · quarter ended Feb 2026

EBITDA growth accelerates

Q2 FY2026 EBITDA of $7.43M rose 28.6% year over year, ahead of the +4.6% change in trailing-twelve-month EBITDA. Sequentially, it rose 220.9% from the prior quarter. Over 3 fiscal years it compounded at -7.7% a year.

Context

  • EBITDA amounted to 18.6% of revenue in FY2025, down 7.2 pp from a year earlier.
  • EBITDA increased in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 3 analysts of $28.55M (+94.2%) for the fiscal year ending Aug 2026, a step up from the -18.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterFeb 2026
$7.43M+220.9% QoQ
Last fiscal yearAug 2025
$14.7M-18.7% YoY
LTMFeb 2026
$17.31M+4.6% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+28.6%+4.4%-24.1 pp
1 year-18.7%+94.2%+112.8 pp
3-year CAGR-7.7%+28.5%+36.2 pp
5-year CAGR+23.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
14.7M USD
Year-over-year change
-18.7%
4-year CAGR
+0.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How SLP compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +4.6% is the 4th highest of 11, against a peer median of -30.3%.
  • EBITDA amounts to 21.5% of revenue for SLP, versus a peer median of 75.1%.
SLP Competitors
EBITDA for SLP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRCNational Research CorporationLTM Mar 2026$27.87M USD-32.4%-15.0%20.1%
OPRXOptimizeRx CorporationLTM Mar 2026$18.9M USD+423.3%—17.6%
SLPSimulations Plus, Inc.LTM Feb 2026$17.31M USD+4.6%-7.7%21.5%
DHDefinitive Healthcare Corp.LTM Mar 2026$11.6M USD+101.6%—4.9%
CLLSCellectis S.A.LTM Mar 2026-$51.11M USD-57.3%—75.1%
ACIUAC Immune S.A.LTM Mar 2026-CHF 64.45M CHF-29.6%—1740.8%
SOPHSOPHiA GENETICS S.A.LTM Mar 2026-$66.08M USD-31.0%—81.4%
ANROAlto Neuroscience, Inc.LTM Mar 2026-$71.29M USD-16.9%——
KRROKorro Bio, Inc.LTM Mar 2026-$78.15M USD+14.5%—2034.0%
NAKANakamoto Inc.LTM Mar 2026-$276.76M USD-6900.5%—7060.9%
AGLAgilon Health, Inc.LTM Mar 2026-$340.64M USD-53.6%—5.9%
Peer median (excluding SLP) —-30.3%-15.0%75.1%

Competitors are the stored peer set for SLP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Aug 2021
FY2022
Aug 2022
FY2023
Aug 2023
FY2024
Aug 2024
FY2025
Aug 2025
Revenue46.47M53.91M59.58M70.01M79.18M
Cost of Revenue10.6M10.82M11.63M26.86M32.96M
Gross Profit35.87M43.08M47.95M43.15M46.22M
Gross Margin77.2%79.9%80.5%61.6%58.4%
Research & Development4.05M3.21M4.5M5.75M6.88M
Selling, General & Admin20.57M24.97M34.72M31.27M32.85M
Operating Expenses24.61M28.17M39.22M37.02M116.95M
Depreciation & Amortization3.59M3.57M3.84M5.67M8.21M
EBITDA14.7M18.69M13.07M18.08M14.7M
EBITDA Margin31.6%34.7%21.9%25.8%18.6%
Operating Income11.25M14.91M8.73M6.13M(70.73M)
Operating Margin24.2%27.7%14.6%8.8%-89.3%
Interest Income201K717K4.13M4.38M722K
Interest Expense22K0000
Other Income / Expenses(168K)204K2.97M6.28M1.35M
Income Before Tax11.09M15.12M11.7M12.41M(69.38M)
Pre-Tax Margin23.9%28.0%19.6%17.7%-87.6%
Income Tax Expense1.3M2.63M1.73M2.46M(4.66M)
Net Income9.78M12.48M9.96M9.95M(64.72M)
Net Margin21.1%23.2%16.7%14.2%-81.7%
EPS (Basic)0.490.620.500.50(3.22)
EPS (Diluted)0.470.600.490.49(3.22)
Weighted Avg Shares20.05M20.2M20.08M19.99M20.1M
Weighted Avg Shares (Diluted)20.74M20.75M20.47M20.3M20.1M

Simulations Plus, Inc.

NASDAQ:SLP

Intrinsic Alpha fair value

Locked

Current Price

$18.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.